Novogenia AG, an international healthcare company specializing in human genetics and personalized products, has announced the U.S. market launch of its new MGT Plus methylation test. This launch, in collaboration with U.S. partner 10X Health, expands their joint product pipeline and reinforces their international collaboration in genetic analysis and longevity. Methylation, a fundamental biochemical process, plays a critical role in numerous metabolic and regulatory functions, influencing the processing of vitamins, neurotransmitters, and other biological molecules.
Unlike commercially available tests that analyze only a limited number of genes, MGT Plus covers 27 genes, offering a comprehensive view of methylation processes across six interconnected biological pathways, including energy and nutrient metabolism, stress and neurotransmitter regulation, and vascular, immune, and cellular health. This broader scope provides more precise insights into key biochemical processes, enabling more personalized prevention and health strategies.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, emphasized the significance of the launch: "With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies. Our close collaboration with our U.S. partner 10X Health underscores our commitment to making scientific innovations accessible internationally and actively advancing personalized approaches to preventive health."
The global direct-to-consumer testing market is experiencing robust growth, reaching approximately $4.7 billion in 2025 and projected to exceed $16.0 billion by 2033. Genetic testing, the largest segment, accounts for over 40% of the market, with North America leading at about 50% of global volume in 2025. This growth is driven by increasing interest in personalized health information and prevention.
Novogenia AG, headquartered in Munich, Germany, operates its own laboratory for genetic analyses used in diagnosis, treatment, and prevention of diseases, as well as in the production of tailored nutritional supplements and cosmetics. The company partners with healthcare professionals to optimize patient care based on genetic predispositions. Additionally, Novogenia holds investments in innovative biotech, healthcare, and life sciences companies. For more information, visit Novogenia AG.
